The price of negative light is a problem. It is also the biggest opportunity to reindustrialize Spain in decades

See the wholesale price of light to zero euros or even negative has ceased to be an anecdote for become a daily phenomenon In Spain. Symptom that renewables dominate the energy mix, is a growing obstacle to the profitability of electricity, but is still cheap energy. And as such, it is the best opportunity to reindustrialize Spain in a long time. Why it happens. “Zero or negative prices are a symptom of abundance of renewable resources to generate electricity,” analyst Pedro Cantuel, who works in Ignis’s energy management, explains to Xataka. In the central hours of the day, when photovoltaic production is massive, renewables flood the network with a practically null marginal cost, which collapses prices in the wholesale market. The time to reindustrialize. The abundance of cheap energy puts Spain in a competitive advantage position against its European neighbors. If Spain can offer clean energy to a very low cost, it becomes a magnet for industries that devour electricity, such as data centers, metallurgy or new green chemical industry. “In the European context, I think this can happen, since Spain could offer more competitive electricity than some of its neighbors,” explains Sergio Fernández Munguía, engineer of the renewable sector and author of Windletter. “In a global context, industrial electricity in Spain is still expensive because the invoice includes many other items beyond the cost of electricity.” Who has to adapt to who. The industrial model of the twentieth century was based on a premise: the energy was available 24/7 at a more or less stable cost. The renewables have broken this scheme: their production is intermittent. The traditional solution is to store that energy with batteries or pumping centrals, but the high cost of these facilities has dragged their deployment. Fernando Rodríguez, an industrial engineer of the energy sector, believes that the true revolution is not only to attract the usual industries, but to create those of tomorrow. The solution, according to Rodríguez, is that the industry adapts to energy until there is economic storage, and not vice versa: “The industry of the future will have to work with greater inventories, as was the case before the imposition of the imposition of the Just in time“ Flexible and modular manufacturing. The idea is to design industrial processes that can operate in full load when energy is almost free and reduce its activity or stop when it is expensive, without losing efficiency. It is already happening in adaptable industries such as recycling, large -scale 3D printing or desalination, which can program their consumption peaks for maximum solar generation hours. Concrete cases? In the United States, the Alcoa Warrick aluminum giant already adjusts its production to the available renewable generation. In Germany, the School of Engineers of Munich and Linde have designed an ammonia plant that works both 100% and 10% of its capacity, adapting to the production of Hydrogen Grandolytic. The industry will be where renewables are. Rodríguez believes that an industrial relocation will be necessary, and gives as an example the failure of the German “electric highways, a project to carry wind energy from the north to the industrial south that will end up costing more than 140,000 million euros. “Industrial companies must relocate near the new centers of gravity of electric production,” he explains. In Spain, this means taking factories to areas with more sun and wind, creating development poles in places that until now were not industrial foci. If energy is free, who will build the central? The cheap energy avalanche has an inevitable counterpart that puts the entire system at risk. If prices are zero, producers’ income are also. “Negative or zero prices discourage new investments,” confirms Sergio Fernández. “Especially in photovoltaic, those who are making numbers for new plants will see that their expected income in the market is lower than a few years ago and, therefore, also their profitability.” A nipe castle. This problem not only affects future renewable plants, but also the support that guarantees that we have light when there is no sun or wind: combined gas cycles. “As the price of the wholesale market falls,” says Fernando Rodríguez, “the growing opportunity cost will leave investments to generation, transport, distribution and marketing without investors and without financing.” The long -term danger is evident: a total break in the investment that leads us to an obsolete and unable to meet future demand. Without a robust system, there is no possible competitive economy. To take advantage of the industrial opportunity, Spain has to strengthen its nipe castle, and it is not enough to touch the prices artificially. The attack plan. The first bottleneck is the electricity bill. Although energy in the wholesale market is cheap, the invoice is still expensive. For Pedro Cantuel, the solution goes through a “drastic reduction in the final invoice eliminating taxes, bringing system charges to the general state budgets and reduce regulated costs.” The second problem is oversupply. How is demand increased? Cantuel proposes to “encourage electrification to replace the consumption of winter gas with electricity.” And at an industrial level, support great consumers “with the same mechanisms that our German or French competitors have, facilitating the connection of new demand to the network. Spain before its historical opportunity. A turning point that can allow the country to reindustrialize sustainably and become an energy power in Europe. But time runs, and it is essential to “create a national long -term plan that provides stability and certainty to the sector,” claims Cantuel, who defines as a priority “set clear rules for storage and new vectors, such as hydrogen.” The relationship between electric and the government is enquisted by the 7% tax on the generation. Consumers complain that the distribution toll “far exceeds real network costs.” Defining the rules of a competitive New Spain requires a country plan that puts all interested parties to row in the same direction. Without an ambitious and coordinated plan, today’s abundance could become the precariousness of tomorrow. In Xataka | The light price is … Read more

The atlas of side effects (positive and negative) of Ozempic discovered | Health and well-being

All medications have side effects, just take a look at any leaflet to see this. But there are not many cases in which these amount to the main effect. This is what happened a few years ago with GLP-1 agonists, medications used for decades to treat type 2 diabetes that began to demonstrate weight-loss effects. After several reformulations, new commercial brands, such as Ozempic and Wegovy, became an effective way to end obesity. But science is proving that there are many other side effects that could become major ones. GLP-1 is a molecular Swiss army knife, a kind of all-purpose drug. They affect our bodies in ways we still don’t fully understand. But today we are closer to listing. A team of scientists from the University of Washington School of Medicine has published the first detailed atlas of the side effects of these drugs. They have found benefits for cognitive and behavioral health, while revealing an increased risk of developing pancreatitis and kidney conditions. “Until now we had seen anecdotes and reports here and there. “Some people saying that it can affect this or that,” explained its main author, the clinical epidemiologist, in the presentation of the study. Ziyad Al-Aly, from the John J. Cochran Veterans Hospital. “But no one, no one had thoroughly investigated the effectiveness and risks of GLP-1 and all the ways it can affect health.” The study was published this Monday in the journal Nature Medicineshowcase of the best world science. More information “We did an analysis that comprehensively mapped the associations between GLP-1 and 175 potential health effects,” Al-Aly notes. The benefits, beyond weight loss, included a lower risk of substance use disorders and a reduction in suicidal ideation, schizophrenia, and other psychotic disorders. They also observed a reduction in cognitive disorders, such as Alzheimer’s and dementia. And finally, a reduction in the risk of clotting disorders, including stroke. “We found that these drugs have a wide range of beneficial effects, but all this does not come without risks,” warns the expert. The study confirms that, in some cases, they can cause gastrointestinal problems, such as nausea and vomiting. This is quite common and has already been documented in some patients. An increased risk of gastroparesis or stomach paralysis in rare cases and an increased risk of low blood pressure have also been seen. The analysis also notes that the drug may increase the risk of sleep problems and headaches, kidney stones, and drug-induced kidney inflammation. For these reasons, the authors recommend that, when evaluating this treatment, it should always be done under medical supervision and after an individualized analysis. “It is an observational study, although it has a large database and has been carried out for a long time,” he explains. Christopher Moralesan endocrinologist at the Virgen Macarena University Hospital in Seville, who was not involved in the study. The study does not demonstrate, therefore, that the medication is the cause of the listed effects. But these are consistent enough (risk reduction between 10 and 20%) and the database large enough (almost two million patients over three years) to think there is a direct relationship. “With Big Data you can scrape these results in very large databases and this is positive. But we must remember that here we can only verify association, not causality.” The objective of this research, in the words of its own authors, was not to analyze a specific effect and demonstrate causality, but to build an atlas of the association of risks and benefits of this relatively new medicine. “It’s like when Christopher Columbus arrived in America, and he thought about mapping it to get his bearings,” explains Al-Aly. “This is what we are doing, drawing a landscape of benefits and risks.” This opens the door to the possibility that in the future, after many reformulations and research, we can talk about an Ozempic for dementia, alcoholism or Alzheimer’s. There is still a long way to go, but this study has drawn a first map to locate the path. And there are many companies willing to embark on this adventure. There is currently a scientific and commercial race to find the next revolutionary use of GLP-1 agonists. Everyone has in mind the case of Novo Nordisk, the Danish laboratory that presented Ozempic in 2018, and which today has a stock market capitalization of 382,000 million dollars, which makes it the largest company in Europe. This has enormous business and economic implications, but from the scientific world, the question is different. How does an anti-diabetes drug have so many and varied effects? “Medicines don’t work surgically. They are designed to do one thing, but the reality is that this is almost never the case,” reflects Al-Aly. “Biology is complex and multiple, and if you touch one thing you will create a network of various effects.” GLP-1 acts on the intestine, but also on the brain, affecting areas that are involved in impulse control and reward signaling. This would explain why they help mitigate addiction problems. These medications would also affect the blood vessels, and in doing so have a potential effect on the heart. There is research that suggests that they also reduce inflammation, including that of the brain, which could explain their protective effect against neurodegenerative diseases. “But there is also another simpler theory that can explain all these positive health effects,” explains Al-Aly. Obesity is considered a disease in itself, but also the gateway to many others. It is the fifth risk factor for death in the world and every year 2.8 million adults die as a result of this condition. “When we treat obesity, it is normal that this affects other diseases, since it is the mother of them all,” summarizes Al-Aly. The expert has not yet decided, with the available scientific evidence, on which of these two theories has more force. The first would mean that we are talking about a miracle drug with multiple uses. The second would be less profitable for companies, would fill … Read more

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.